stockrow
Saturday 7 November 2026
Export PMVP’s income statement to Excel — free account
PMV Pharmaceuticals, Inc.
PMVP Healthcare Biotechnology
- EPS
- +17.1%
- Free cash flow
- +20.3%
Quarter to June 2026, against a year earlier
1.25
0.03
−2.34%
Follow PMVP
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 5 | 5 | 22 | +109.5% | |
| Gross margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | — | — | (18) | (25) | (34) | (58) | (73) | (69) | (75) | (80) | (75) | +24.2% | ||||||
| EBT margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | 0 | (18) | (25) | (34) | (58) | (73) | (69) | (59) | (78) | (75) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | (5.82) | (8.35) | (2.40) | (1.28) | (1.61) | (1.44) | (1.14) | (1.48) | (1.42) | (17.8%) | ||||||
| Cash flow | — | — | (5.04) | (7.27) | (2.28) | (1.03) | (1.40) | (1.16) | (0.99) | (1.40) | (1.33) | (16.7%) | ||||||
| Capex | — | — | (0.15) | (0.04) | (0.01) | (0.03) | (0.18) | (0.02) | (0.01) | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | (5.19) | (7.31) | (2.29) | (1.06) | (1.57) | (1.18) | (1.00) | (1.40) | (1.33) | (17.1%) | ||||||
| Book value | — | — | 0.00 | (23.22) | 25.00 | 6.84 | 5.40 | 4.70 | 3.41 | 1.99 | 1.34 | n/m | ||||||
| Shares, m | — | — | 3 | 3 | 14 | 45 | 46 | 48 | 52 | 53 | 53 | +50.4% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | (15) | (22) | (33) | (47) | (64) | (56) | (51) | (74) | (71) | +25.3% | |||||
| Capex | — | — | 0 | 0 | 0 | (1) | (8) | (1) | 0 | 0 | 0 | n/m | ||||||
| Free cash flow | — | — | (16) | (22) | (33) | (48) | (72) | (57) | (52) | (74) | (71) | +24.8% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | 60 | 98 | 358 | 289 | 236 | 193 | 161 | 104 | 71 | +8.2% | |||||
| Net debt | — | — | (62) | (101) | (361) | (298) | (242) | (204) | (169) | (113) | (79) | +9.0% | ||||||
| Shareholders’ equity | — | — | — | (70) | 359 | 309 | 246 | 226 | 176 | 105 | 72 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | 0.00 | (49.21) | (14.70) | (16.60) | (24.36) | (26.40) | (26.48) | (50.51) | (64.04) | (50.5) pt | |||||
| ROIC | — | — | 0.00 | 0.00 | 0.00 | (344.55) | (1,159.68) | (229.63) | (805.99) | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | 30.08 | 43.48 | (23.86) | (17.33) | (26.44) | (29.24) | (29.23) | (55.37) | (70.93) | (85.4) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | 38 | 44 | 54 | 62 | 63 | 47 | 54 | — | +6.0% | |||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
PMV Pharmaceuticals, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| IMUX Immunic, Inc. | $99.9M | — (loss-making) | — | — | n/m | −26.79% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| NRXP NRx Pharmaceuticals, Inc. | $98.3M | — (loss-making) | — (loss-making) | — | n/m | −142.60% (below 0%: shrinking) | 38.69% | (590.83%) | Compare |
| UNCY Unicycive Therapeutics, Inc. | $96.9M | — (loss-making) | — (loss-making) | — | n/m | +9.77% (above 0%: growing) | 0.00% | 0.00% | Compare |
| PMVP PMV Pharmaceuticals, Inc. | $96.3M | — (loss-making) | — | — | n/m | +20.27% (above 0%: growing) | 0.00% | 0.00% | |
| BDTX Black Diamond Therapeutics, Inc. | $95.4M | — (loss-making) | — (loss-making) | — | n/m | +12.91% (above 0%: growing) | 100.00% | 0.00% | Compare |
| LENZ LENZ Therapeutics, Inc. | $94.6M | — (loss-making) | — (loss-making) | −72.93% (below 0%: shrinking) | n/m | −147.16% (below 0%: shrinking) | 86.58% | (972.75%) | Compare |
| VANI Vivani Medical, Inc. | $93.8M | — (loss-making) | — (loss-making) | −71.87% (below 0%: shrinking) | n/m | +0.39% (above 0%: growing) | 0.00% | 0.00% | Compare |
| VXRT VAXART, INC. | $92.4M | 2.8× | — (loss-making) | −85.33% (below 0%: shrinking) | n/m | −57.23% (below 0%: shrinking) | 100.00% | (162.74%) | Compare |
| NMRA Neumora Therapeutics, Inc. | $91.5M | — (loss-making) | — | — | n/m | +24.45% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $95.0M | — | — | −72.93% | — | −13.20% | 19.35% | 0.00% |
Pay and ownership Proxy statement filed 22 April 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 1.67m | 958.18k | 14.37 |
| 2024 | 4.76m | 2.17m | 6.54 |
| 2023 | 2.21m | 513.65k | 13.42 |
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Read the proxy statement